Intrapericardial infusion of etoposide and cisplatin in treating malignant pericardial effusion of non-small cell lung cancer

• Published in: Ai zheng = Aizheng = Chinese journal of cancer Vol. 25; no. 4; p. 505
• Main Authors: Chen, Li-Kun, Xu, Guang-Chuan, Liang, Ying, Yang, Qun-Ying, Zhang, Li-Na
• Format: Journal Article
• Language: Chinese
• Published: China 01.04.2006
• Subjects: Adult; Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Non-Small-Cell Lung - complications; Carcinoma, Non-Small-Cell Lung - drug therapy; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cisplatin - therapeutic use; Drug Therapy, Combination; Etoposide - administration & dosage; Etoposide - adverse effects; Etoposide - therapeutic use; Female; Follow-Up Studies; Humans; Leukopenia - chemically induced; Lung Neoplasms - complications; Lung Neoplasms - drug therapy; Male; Middle Aged; Pericardial Effusion - drug therapy; Pericardial Effusion - etiology; Pericardiocentesis; Survival Rate

Pericardiocentesis and intrapericardial infusion of chemotherapeutic drugs is the main treatment of malignant pericardial effusion. This study was to observe the efficacy and side effect of intrapericardial infusion of etoposide (VP-16) and cisplatin (DDP) on malignant pericardial effusion of non-small cell lung cancer (NSCLC). Twenty-eight NSCLC patients with malignant pericardial effusion were treated with pericardiocentesis and intrapericardial infusion of VP-16 (200-300 mg) and DDP (80-100 mg). Intravenous chemotherapy were given 2 weeks after the pericardiocentesis. The overall response(OR) rate of the first-time treatment of the 28 patients was 85.7%, with complete response (CR) rate of 71.4%; the OR rate of the second-time treatment was 100%. Only 4 patients needed second-time pericardiocentesis. Sixteen patients developed gastrointestinal tract reaction (mainly grade I-II), 12 developed myelosuppression (mainly grade I), and 1 showed mild abnormal of transaminase. For the 24 naïve patients, the overal